证券日报网讯 8月22日晚间，鱼跃医疗发布关于公司2025年半年度利润分配方案的公告称，公司拟向全 体股东每10股派发现金红利2.00元（含税）。按照目前公司总股本1，002，476，929股为基数进行计 算，预计本次派发现金红利总额为200，495，385.80元。 （编辑 任世碧） ...

Core Viewpoint - The CSI All Share Healthcare Equipment and Services Index has shown significant growth, reflecting a positive trend in the healthcare sector, with a notable increase in trading volume and index performance over various time frames [1][2]. Group 1: Index Performance - The CSI All Share Healthcare Equipment and Services Index rose by 0.14% to 15,554.17 points, with a trading volume of 35.351 billion [1]. - Over the past month, the index has increased by 10.85%, by 14.71% over the last three months, and by 13.47% year-to-date [1]. Group 2: Index Composition - The index comprises companies related to the healthcare theme, with the top ten weighted companies being Mindray Medical (9.17%), United Imaging (7.63%), Aier Eye Hospital (7.12%), and others [1]. - The index is primarily composed of companies listed on the Shenzhen Stock Exchange (59.89%) and the Shanghai Stock Exchange (40.11%) [1]. Group 3: Industry Representation - The index exclusively represents the healthcare sector, with a 100% allocation to pharmaceutical and healthcare-related companies [2]. - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2]. Group 4: Investment Products - Several public funds track the CSI All Share Healthcare Equipment and Services Index, including various Southern and Tianhong funds, as well as ETFs from different asset management companies [2].

Core Insights - Yuyue Medical reported a revenue of 4.659 billion yuan for the first half of 2025, representing a year-on-year growth of 8.16%, and a net profit attributable to shareholders of 1.203 billion yuan, up 7.37% year-on-year [1] - The company is focusing on technological innovation, applying AI and other advanced technologies in product development and operational management, while building a comprehensive product ecosystem centered on digitalization and wearability [1][3] - Yuyue Medical is committed to expanding its global presence, enhancing overseas channel construction, and nurturing international talent to tap into the vast potential of the global market [1] Business Performance - The respiratory therapy solutions generated revenue of 1.674 billion yuan, a year-on-year increase of 1.93%, while blood glucose management and POCT solutions achieved revenue of 674 million yuan, growing by 20.00% [2] - Emergency solutions and other segments reported revenue of 136 million yuan, up 30.54%, and home health testing solutions reached 1.014 billion yuan, increasing by 15.22% [2] - Clinical instruments and rehabilitation solutions generated revenue of 1.134 billion yuan, reflecting a growth of 3.32%, showcasing the company's strong position in the home medical device sector [2] R&D and Innovation - Yuyue Medical invested 295 million yuan in R&D during the first half of 2025, marking a 9.44% increase year-on-year, with total R&D investment exceeding 2.4 billion yuan over the past five years [2] - The company has launched several new products, including the Anytime5 glucose monitoring system and portable AEDs, while accelerating the IoT integration of its products to provide comprehensive health management solutions [2][4] Global Strategy - The company achieved overseas revenue of 607 million yuan, a year-on-year growth of 26.63%, and obtained 85 international registrations to support global product promotion [3] - Yuyue Medical is enhancing its overseas team and local sales network to ensure the successful establishment and growth of its international business [3] Ecosystem Development - Yuyue Medical is building an integrated health management ecosystem that combines hardware, software, and data, launching the Yuyue AI Agent health management application to enhance user engagement and data management [4] - The company emphasizes the development of AI-enabled wearable medical devices for continuous monitoring of health indicators such as blood glucose and blood pressure [3][4] Future Outlook - The chairman of Yuyue Medical stated the company's commitment to long-termism, global vision, and strategic calibration, with a focus on AI as a lever for deepening globalization, digitalization, and wearability strategies [4]

Core Insights - Yuyue Medical reported a revenue of 4.659 billion yuan for the first half of 2025, representing a year-on-year growth of 8.16%, and a net profit attributable to shareholders of 1.203 billion yuan, up 7.37% year-on-year [1] - The company is focusing on three strategic directions: globalization, digitalization, and wearability, aiming to establish a solid foundation for long-term development [1] Business Performance - The respiratory therapy solutions generated revenue of 1.674 billion yuan, a year-on-year increase of 1.93% [2] - Blood glucose management and POCT solutions achieved revenue of 674 million yuan, growing by 20.00% [2] - Emergency solutions and other segments reported revenue of 136 million yuan, up 30.54% [2] - Home health monitoring solutions earned 1.014 billion yuan, with a growth of 15.22% [2] - Clinical instruments and rehabilitation solutions generated revenue of 1.134 billion yuan, increasing by 3.32% [2] - The company maintains its leadership in the home medical device sector with steady growth across diverse business segments [2] Technological Advancements - Yuyue Medical has made significant progress in AI healthcare, integrating artificial intelligence, big data, and IoT into its operations and product development [2] - The company is focusing on developing AI-enabled wearable medical devices that monitor blood glucose, blood pressure, and blood oxygen levels [2] Future Outlook - The chairman of Yuyue Medical emphasized a commitment to long-termism, a global perspective, and leveraging AI to deepen the company's strategies in globalization, digitalization, and wearability [3]

Company Overview - Yuyue Medical reported a total operating revenue of 4.659 billion yuan for the first half of 2025, representing an 8.16% increase compared to the same period last year [1] - The net profit for the same period was 1.203 billion yuan, reflecting a growth of 7.37% year-on-year [1] - Earnings per share stood at 1.2049 yuan, with a return on equity of 9.21% [1] - The operating cash flow per share was 1.1640 yuan, and the gross profit margin was 50.37% [1] Industry Position - Yuyue Medical, established in 1998, is located in Danyang City, Jiangsu Province, and primarily engages in the provision of home medical devices, clinical medical products, and related medical services [1] - The company has a registered capital of 1.002 billion yuan and is represented by its legal representative, Wu Qun [1] Investment and Intellectual Property - Yuyue Medical has made investments in 36 companies and participated in 2,166 bidding projects [1] - The company holds 719 trademark registrations and 1,016 patent registrations, along with 2,294 administrative licenses [1]

鱼跃医疗8月22日晚间发布公告称，公司第六届第五次董事会会议于2025年8月22日以通讯表决的方式召 开。会议审议了《公司2025年半年度报告及其摘要》等文件。 （文章来源：每日经济新闻） ...

Core Viewpoint - Yuyue Medical (002223.SZ) reported a revenue of 4.659 billion yuan for the first half of 2025, reflecting a year-on-year growth of 8.16% [1] - The net profit attributable to shareholders reached 1.203 billion yuan, an increase of 7.37% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 914 million yuan, showing a decline of 5.22% year-on-year [1] Financial Performance - Revenue for the first half of 2025: 4.659 billion yuan, up 8.16% year-on-year [1] - Net profit attributable to shareholders: 1.203 billion yuan, up 7.37% year-on-year [1] - Net profit after deducting non-recurring gains: 914 million yuan, down 5.22% year-on-year [1] - Basic earnings per share: 1.2049 yuan [1] Dividend Distribution - The company plans to distribute a cash dividend of 2 yuan (including tax) for every 10 shares to all shareholders [1]

江苏鱼跃医疗设备股份有限公司 2025 年上半年度 财务报告 （未经审计） 资产负债表 | 编制单位:江苏鱼跃医疗设备股份有限公司 | 2025 | 年 6 月 30 日 | | 单位:人民币元 | | --- | --- | --- | --- | --- | | 资 产 | 期末余额 | | 期初余额 | | | | 合并数 | 母公司 | 合并数 | 母公司 | | 流动资产： | | | | | | 货币资金 | 7,230,481,000.15 | 6,559,853,482.27 | 6,618,648,637.69 | 6,134,712,052.65 | | 结算备付金 | | | | | | 拆出资金 | | | | | | 交易性金融资产 | | | | | | 衍生金融资产 | | | | | | 应收票据 | 12,063,446.19 | 6,600,467.24 | 26,877,764.76 | 22,399,504.25 | | 应收账款 | 1,184,722,827.85 | 825,331,349.57 | 715,146,307.99 | 587,531,287.27 ...

江苏鱼跃医疗设备股份有限公司（以下简称"公司"）于 2025 年 8 月 22 日召开第六届董事会第五次会议，审议通过了《关于 2021 年度第一期员工持股 计划存续期展期的议案》，同意将公司 2021 年度第一期员工持股计划（以下简 称"本次员工持股计划"）的存续期展期 24 个月，即展期至 2027 年 8 月 26 日。 现将相关事项公告如下： 证券代码：002223 证券简称：鱼跃医疗 公告编号：2025-030 江苏鱼跃医疗设备股份有限公司 关于 2021 年度第一期员工持股计划存续期展期的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 三、备查文件 1、公司第六届董事会第五次会议决议； 一、本次员工持股计划的基本情况 公司于 2021 年 6 月 17 日召开第五届董事会第八次临时会议和第五届监事会 第四次临时会议，于 2021 年 7 月 5 日召开 2021 年第一次临时股东大会，审议通 过了《公司 2021 年度第一期员工持股计划（草案）及其摘要》等相关议案。具 体内容详见公司于 2021 年 6 月 18 日和 2021 年 7 月 6 ...

江苏鱼跃医疗设备股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | | | | | | | | | | 单位：万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 资金占用 | 占用方与 上市公司 | 上市公司核 | 2025 年期初 | 2025 年 1-6 月占用累计 | 2025年1-6 月占用资 | 2025 年 1-6 | 2025 年 6 月 | 占用形成 | | | 非经营性资金占用 | 方名称 | 的关联关 | 算的会计科 | 占用资金余 | 发生金额 | 金的利息 | 月偿还累计 | 30 日占用资 | 原因 | 占用性质 | | | | | 目 | 额 | （不含利 | | 发生金额 | 金余额 | | | | | | 系 | | | | （如有） | | | | | | | | | | | 息） | | | | | | | 控股股东、实际控制 | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | 小 ...